These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

908 related articles for article (PubMed ID: 20186853)

  • 1. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging.
    Morris JC; Roe CM; Xiong C; Fagan AM; Goate AM; Holtzman DM; Mintun MA
    Ann Neurol; 2010 Jan; 67(1):122-31. PubMed ID: 20186853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sex-Specific Association of Apolipoprotein E With Cerebrospinal Fluid Levels of Tau.
    Hohman TJ; Dumitrescu L; Barnes LL; Thambisetty M; Beecham G; Kunkle B; Gifford KA; Bush WS; Chibnik LB; Mukherjee S; De Jager PL; Kukull W; Crane PK; Resnick SM; Keene CD; Montine TJ; Schellenberg GD; Haines JL; Zetterberg H; Blennow K; Larson EB; Johnson SC; Albert M; Bennett DA; Schneider JA; Jefferson AL;
    JAMA Neurol; 2018 Aug; 75(8):989-998. PubMed ID: 29801024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls.
    Martínez-Morillo E; Hansson O; Atagi Y; Bu G; Minthon L; Diamandis EP; Nielsen HM
    Acta Neuropathol; 2014 May; 127(5):633-43. PubMed ID: 24633805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.
    Sutphen CL; Jasielec MS; Shah AR; Macy EM; Xiong C; Vlassenko AG; Benzinger TL; Stoops EE; Vanderstichele HM; Brix B; Darby HD; Vandijck ML; Ladenson JH; Morris JC; Holtzman DM; Fagan AM
    JAMA Neurol; 2015 Sep; 72(9):1029-42. PubMed ID: 26147946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cortical binding of pittsburgh compound B, an endophenotype for genetic studies of Alzheimer's disease.
    Hinrichs AL; Mintun MA; Head D; Fagan AM; Holtzman DM; Morris JC; Goate AM
    Biol Psychiatry; 2010 Mar; 67(6):581-3. PubMed ID: 19892322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exercise and Alzheimer's disease biomarkers in cognitively normal older adults.
    Liang KY; Mintun MA; Fagan AM; Goate AM; Bugg JM; Holtzman DM; Morris JC; Head D
    Ann Neurol; 2010 Sep; 68(3):311-8. PubMed ID: 20818789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apolipoprotein E epsilon4 does not modulate amyloid-β-associated neurodegeneration in preclinical Alzheimer disease.
    Desikan RS; McEvoy LK; Holland D; Thompson WK; Brewer JB; Aisen PS; Andreassen OA; Hyman BT; Sperling RA; Dale AM;
    AJNR Am J Neuroradiol; 2013 Mar; 34(3):505-10. PubMed ID: 22976236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proximity to Parental Symptom Onset and Amyloid-β Burden in Sporadic Alzheimer Disease.
    Villeneuve S; Vogel JW; Gonneaud J; Pichet Binette A; Rosa-Neto P; Gauthier S; Bateman RJ; Fagan AM; Morris JC; Benzinger TLS; Johnson SC; Breitner JCS; Poirier J;
    JAMA Neurol; 2018 May; 75(5):608-619. PubMed ID: 29482212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction between sleep-disordered breathing and apolipoprotein E genotype on cerebrospinal fluid biomarkers for Alzheimer's disease in cognitively normal elderly individuals.
    Osorio RS; Ayappa I; Mantua J; Gumb T; Varga A; Mooney AM; Burschtin OE; Taxin Z; During E; Spector N; Biagioni M; Pirraglia E; Lau H; Zetterberg H; Blennow K; Lu SE; Mosconi L; Glodzik L; Rapoport DM; de Leon MJ
    Neurobiol Aging; 2014 Jun; 35(6):1318-24. PubMed ID: 24439479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of analytical platforms for cerebrospinal fluid measures of β-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology.
    Fagan AM; Shaw LM; Xiong C; Vanderstichele H; Mintun MA; Trojanowski JQ; Coart E; Morris JC; Holtzman DM
    Arch Neurol; 2011 Sep; 68(9):1137-44. PubMed ID: 21555603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in Aβ biomarkers and associations with APOE genotype in 2 longitudinal cohorts.
    Resnick SM; Bilgel M; Moghekar A; An Y; Cai Q; Wang MC; Thambisetty M; Prince JL; Zhou Y; Soldan A; Wong DF; O'Brien RJ; Ferrucci L; Albert MS
    Neurobiol Aging; 2015 Aug; 36(8):2333-9. PubMed ID: 26004017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal β-Amyloid Deposition and Hippocampal Volume in Preclinical Alzheimer Disease and Suspected Non-Alzheimer Disease Pathophysiology.
    Gordon BA; Blazey T; Su Y; Fagan AM; Holtzman DM; Morris JC; Benzinger TL
    JAMA Neurol; 2016 Oct; 73(10):1192-1200. PubMed ID: 27548756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease.
    Vemuri P; Wiste HJ; Weigand SD; Knopman DS; Shaw LM; Trojanowski JQ; Aisen PS; Weiner M; Petersen RC; Jack CR;
    Ann Neurol; 2010 Mar; 67(3):308-16. PubMed ID: 20373342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of normal aging and ApoE genotype on the levels of CSF biomarkers for Alzheimer's disease.
    Glodzik-Sobanska L; Pirraglia E; Brys M; de Santi S; Mosconi L; Rich KE; Switalski R; Saint Louis L; Sadowski MJ; Martiniuk F; Mehta P; Pratico D; Zinkowski RP; Blennow K; de Leon MJ
    Neurobiol Aging; 2009 May; 30(5):672-81. PubMed ID: 17920160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequence of Alzheimer disease biomarker changes in cognitively normal adults: A cross-sectional study.
    Luo J; Agboola F; Grant E; Masters CL; Albert MS; Johnson SC; McDade EM; Vöglein J; Fagan AM; Benzinger T; Massoumzadeh P; Hassenstab J; Bateman RJ; Morris JC; Perrin RJ; Chhatwal J; Jucker M; Ghetti B; Cruchaga C; Graff-Radford NR; Schofield PR; Mori H; Xiong C
    Neurology; 2020 Dec; 95(23):e3104-e3116. PubMed ID: 32873693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical evidence of Alzheimer changes: convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography findings.
    Petrie EC; Cross DJ; Galasko D; Schellenberg GD; Raskind MA; Peskind ER; Minoshima S
    Arch Neurol; 2009 May; 66(5):632-7. PubMed ID: 19433663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly.
    Fagan AM; Head D; Shah AR; Marcus D; Mintun M; Morris JC; Holtzman DM
    Ann Neurol; 2009 Feb; 65(2):176-83. PubMed ID: 19260027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal MRI study.
    Tosun D; Schuff N; Truran-Sacrey D; Shaw LM; Trojanowski JQ; Aisen P; Peterson R; Weiner MW;
    Neurobiol Aging; 2010 Aug; 31(8):1340-54. PubMed ID: 20570401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
    Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
    J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.